Provided by Tiger Trade Technology Pte. Ltd.

SELLAS Life Sciences Group Inc.

14.33
-1.1350-7.34%
Pre-market: 14.450.1250+0.87%07:43 EDT
Volume:8.82M
Turnover:127.17M
Market Cap:2.89B
PE:-67.47
High:15.48
Open:15.48
Low:13.91
Close:15.46
52wk High:15.88
52wk Low:1.39
Shares:201.95M
Float Shares:199.00M
Volume Ratio:1.04
T/O Rate:4.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2123
EPS(LYR):-0.2463
ROE:-39.63%
ROA:-23.30%
PB:21.02
PE(LYR):-58.15

Loading ...

SELLAS Life Sciences Gr Q4 EPS $(0.05) Beats $(0.07) Estimate

Benzinga Earnings
·
Mar 20

SELLAS Life Sciences 2025 net loss narrows, cash position strengthens

Reuters
·
Mar 20

BRIEF-SELLAS Life Sciences FY Net Income USD -26.863 Million

Reuters
·
Mar 20

Sellas Life Sciences FY Operating Income USD -28.274 Million

THOMSON REUTERS
·
Mar 20

Press Release: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 20

Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million

Reuters
·
Mar 20

Sellas Life Sciences options imply 6.2% move in share price post-earnings

TIPRANKS
·
Mar 20

Canaccord Genuity Reaffirms Their Buy Rating on Solstice Minerals Limited (SLS)

TIPRANKS
·
Mar 19

Sims Scores Upbeat Fiscal 2026 Guidance on Americas JV Strength

MT Newswires Live
·
Mar 19

Guess which ASX 200 stock is jumping 17% on strong FY26 guidance

MotleyFool
·
Mar 18

Sellas Life Sciences to present preclinical SLS009 data at AACR conference

TIPRANKS
·
Mar 18

SELLAS Life Sciences to present SLS009 AML preclinical data at AACR poster session

Reuters
·
Mar 18

Sellas Life Sciences Group Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Mar 16

SELLAS (SLS): Advancing AML Pipeline, Strengthened Balance Sheet, and Upcoming Catalysts Drive Higher Target and Buy Rating

TIPRANKS
·
Mar 14

Sellas Life Sciences enrolls first patient in 80-patient Phase 2 SLS009 first-line AML trial

Reuters
·
Mar 12

Sellas Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line Aml Trial of Sls009

THOMSON REUTERS
·
Mar 12

Sellas Life Sciences Group Inc - Topline Data From Phase 2 Trial Expected in Q4 2026

THOMSON REUTERS
·
Mar 12

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

GlobeNewswire
·
Mar 12

What's Going With SELLAS Life Sciences Stock On Wednesday?

Benzinga_recent_news
·
Mar 05

NASA Announces Unexpected Additional Crewed Test Flight for Moon Program

Deep News
·
Feb 28